PDS Biotechnology Corporation

NASDAQ:PDSB

Biotechnology

Healthcare
$0.92 +1.21%

+$0.01 today

Market cap
$51.58M
Beta
1.56
P/E (TTM)
-1.5
EPS (TTM)
-$0.60
52W Low $0.51High $1.67

Volume 5.25M

Average 1.04M

PDSB Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

PDS Biotechnology CorporationNASDAQ: PDSB

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt falls 58.3% from a year ago

Short-term debt stood at $5.21M at the end of Q1 FY2026, down 58.3% from a year earlier and up 1.5% from the prior quarter.

Context

  • Short-term debt amounted to 21.1% of total assets at the end of Q1 FY2026, down 5.5 pp from a year earlier.
  • Short-term debt increased in 2 of the last 3 fiscal years.

What to watch

Whether short-term debt keeps falling in the next quarterly balance sheet after a -58.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.21M+1.5% QoQ
Last fiscal yearDec 2025
$5.13M-59.0% YoY
Year agoMar 2025
$12.5M-58.3% since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-58.3%——
1 year-59.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
5.13M USD
Year-over-year change
-59.0%

Short-term Debt vs competitors

How PDSB compares with its peers on the latest reported figures

  • PDSB's Mar 2026 short-term debt of $5.21M is the highest of the 6 companies compared; the peer median is $0.
  • Its year-over-year change of -58.3% is the highest of 2, against a peer median of -100.0%.
  • Short-term debt amounts to 21.1% of total assets for PDSB, versus a peer median of 0.0%.
PDSB Competitors Peer median
Short-term Debt for PDSB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PDSBPDS Biotechnology CorporationMar 2026$5.21M -58.3%—21.1%
INMBINmune Bio, Inc.Mar 2026$704K ——2.7%
OKUROnKure Therapeutics, Inc.Mar 2026$0 ——0.0%
XLOXilio Therapeutics, Inc.Mar 2026$0 ——0.0%
ATNMActinium Pharmaceuticals, Inc.Jun 2026$0 -100.0%—0.0%
ANVSAnnovis Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding PDSB) $0-100.0%—0.0%

Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents65.24M73.82M56.56M41.69M26.71M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets02.66M2.49M3.36M1.54M
Total Current Assets66.84M76.48M59.06M45.05M28.25M
Property, Plant & Equipment (Net)357.7K527.53K335.01K304.21K243.7K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00002M
Total Non-current Assets357.7K527.53K335.01K304.21K2.24M
Total Assets67.2M77.01M59.39M45.36M30.49M
Account Payables1.31M1.22M6.98M1.68M3.57M
Short-term Debt004.17M12.5M5.13M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities729.39K1.84M1.29M663.4K271.74K
Total Current Liabilities3.76M9.82M13.63M17.09M9.48M
Long-term Debt023.02M19.51M9.2M11.73M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities231.43K23.18M19.63M9.27M11.76M
Total Liabilities3.99M33.01M33.26M26.35M21.24M
Common Stock9.39K9.96K10.92K12.54K18.11K
Retained Earnings(60.7M)(101.56M)(144.5M)(182.11M)(216.61M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity63.21M44M26.13M19M9.25M
Total Debt490.35K23.47M23.85M21.83M16.93M
Net Debt(64.75M)(50.35M)(32.71M)(19.86M)(9.79M)

PDS Biotechnology Corporation

NASDAQ:PDSB

Intrinsic Alpha fair value

Locked

Current Price

$0.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.